ArticleFrontiers in endocrinology2026
Coexistent Hashimoto's thyroiditis modulates lymph node metastasis burden in papillary thyroid carcinoma: a single-center study in South China.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the impact of Hashimoto's thyroiditis (HT) on central lymph node metastasis (CLNM) patterns and identify independent risk factors for CLNM in patients with papillary thyroid carcinoma (PTC). Methods: This retrospective study enrolled 668 cN0 PTC patients who underwent initial surgery at Huizhou Central People's Hospital between August 2024 and July 2025. Patients were stratified into an HT-PTC group (n = 117) and a PTC-only group (n = 551) based on postoperative histopathological findings. Clinicopathological features and CLNM characteristics were systematically compared. Multivariable logistic regression was utilized to identify independent risk factors for CLNM in patients with HT-PTC, and the predictive efficacy of the resulting model was validated using ROC curves. Results: The HT-PTC group exhibited significantly higher rates of multifocality and central lymph node dissection, alongside lower BMI and serum thyroglobulin (Tg) levels, compared with the PTC-only group (all Conclusion: Concomitant HT is associated with a reduced metastatic burden rather than an increased prevalence of CLNM in patients with PTC. Tumor diameter > 1 cm serves as an independent predictor of CLNM. For HT-PTC patients with tumors ≤ 1 cm and no other high-risk factors, the necessity of prophylactic central lymph node dissection warrants individualized assessment combining clinical data and intraoperative observations to avoid overtreatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.